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Cohort profile
AbstrACt
Purpose The Dutch IBD Biobank aims to facilitate the 
discovery of predictors for individual disease course 
and treatment response in patients with inflammatory 
bowel disease (IBD). In this paper, we aim to describe the 
establishment of the Dutch IBD Biobank, including the 
facilitators and barriers to establishment. Moreover, we 
aim to provide a complete overview of the content of the 
Dutch IBD Biobank.
Participants Since 2007, every patient with IBD treated 
in one of the eight Dutch university medical centres is 
asked to participate in the Dutch IBD Biobank in which 
225 standardised IBD-related data items and biomaterials, 
such as serum, DNA, biopsies and a stool sample, are 
collected.
Findings to date As of June 2014, the Dutch IBD Biobank 
had enrolled 3388 patients with IBD: 2118 Crohn’s 
disease (62.5%), 1190 ulcerative colitis (35.1%), 74 IBD-
unclassified (2.2%) and 6 IBD-indeterminate (0.2%). The 
inclusion of patients with IBD is ongoing. The quality of the 
biomaterials is good and serum, DNA and biopsies have 
been used in newly published studies.
Future plans The genotyping (750 000 genetic variants) 
of all participants of the Dutch IBD Biobank is currently 
ongoing, enabling more genetic research. In addition, 
all participants will start reporting disease activity and 
outcome measures using an online platform and  
mobile app.
IntroduCtIon
Inflammatory bowel disease (IBD) is a chronic 
inflammatory disease of the gut comprising 
Crohn’s disease (CD) and ulcerative colitis 
(UC). Of the 17 million inhabitants in the 
Netherlands, 39 000 individuals have been 
diagnosed with CD and 48 000 individuals 
with UC.1 Approximately 39 new individuals 
per 100 000 are newly diagnosed with IBD 
every year. This incidence rate continues to 
rise, posing an increasing burden on society.2 
The clinical symptoms of IBD consist of diar-
rhoea, abdominal discomfort, weight loss, 
fatigue and rectal bleeding. However, these 
symptoms vary greatly both between individ-
uals and in time. Some patients with IBD have 
a relatively mild disease course, requiring 
only limited therapeutic intervention, while 
others have a severe disease course with 
frequent flares requiring expensive medical 
and surgical interventions.
In recent years, many case–control studies 
have been performed to identify factors 
that can explain the onset of IBD. Genome-
wide association studies (GWAS) have iden-
tified 200 genomic loci that are involved in 
the onset of IBD.3 Epidemiological studies 
have identified environmental risk factors 
including smoking, appendectomy, infec-
tions, antibiotics, diet and lifestyle (stress, lack 
strengths and limitations of this study
 ► A major strength of the Dutch IBD Biobank is its 
prospective design.
 ► Another strength is the participation of all eight 
university medical centres in the Netherlands.
 ► The data records are complete and the biomaterials 
have successfully been used in several experiments.
 ► A weakness is the selection bias, because all 
university medical centres in the Dutch IBD Biobank 
are tertiary referral centres.
 ► A major challenge was the establishment of the local 
and central information technology infrastructure.
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of sleep and/or exercise) that could trigger the onset of 
IBD.4 Studies on the bacterial composition of the gut (the 
gut microbiota) have identified distinct microbial compo-
sitions associated with IBD.5 6 Unfortunately, these studies 
provide little insight into reasons for the heterogeneous 
clinical presentation and disease course of patients with 
IBD. As a consequence, limited progress has been made 
in translating basic science into personalised treatment. 
Predicting individual disease outcome and tailoring IBD 
treatment requires prospective patient data on disease 
activity, complications and treatment, as well as bio 
materials and -omics data (genome, transcriptome and gut 
microbiome), in order to link biomarkers to disease. To 
this aim, the prospective Dutch IBD Biobank was created. 
A new national institute to facilitate the biobank and 
other national biobanks was founded by the Dutch Feder-
ation of University Medical Centres (NFU) in 2007 and 
called the Parelsnoer Institute (PSI).7 Gastroenterologists 
who specialised in treating patients with IBD in all eight 
Dutch university medical centres (UMC), together with 
a team of information architects and laboratory experts, 
built up the Dutch IBD Biobank.
The main objective of the biobank is to facilitate the 
discovery of predictors (both epidemiological risk factors 
and biomarkers) for individual disease course and treat-
ment response, by:
1. providing full clinical records of patients describing 
their individual disease course over a prolonged 
period of time;
2. providing high-quality biomaterials;
3. standardising patient data collection and 
questionnaires during outpatient clinic visits and 
thereby improving clinical care.
The aim of this paper is to inform the IBD research 
community about the existence of the Dutch IBD Biobank 
and to give an elaborate overview of the establishment 
process as well as the content.
Cohort desCrIPtIon
design, participating centres and the dutch healthcare setting
The Dutch IBD Biobank is a prospective, nation-
wide biobank in which both data and biomaterials are 
collected. In the Netherlands, there are approximately 80 
hospitals and 8 UMCs (tertiary referral centres), where 
patients with complex IBD are referred to. All eight 
Dutch UMCs participate in the Dutch IBD Biobank. The 
Dutch UMCs are: the Amsterdam Medical Centre in 
Amsterdam, the Erasmus Medical Centre in Rotterdam, 
the Leiden University Medical Centre in Leiden (LUMC), 
the Maastricht University Medical Centre in Maastricht 
(MUMC), the Radboud University Nijmegen Medical 
Centre in Nijmegen, the University Medical Center Gron-
ingen in Groningen (UMCG), the University Medical 
Centre Utrecht in Utrecht and the VU (Vrije Universi-
teit) University Medical Centre in Amsterdam. PSI and 
the Dutch IBD Biobank are part of the Biobanking and 
Biomolecular Resources Research Infrastructure of the 
Netherlands (BBMRI-NL). This is the Dutch national 
node of BBMRI-ERIC, the largest research infrastructure 
project in Europe.8
standardised data collection: the information model
Gastroenterologists from each of the eight UMCs 
convened to design the information model based on 
literature review and clinical standards. A working group 
of gastroenterologists made a longlist of data items 
including a definition for each data item. This longlist was 
subsequently discussed during a meeting in 2006, where 
one or more representatives from each Dutch UMC 
were present. Data items and definitions were accepted, 
modified if deemed necessary, or rejected if deemed not 
part of the core data set. This process was repeated until 
consensus was reached. The Dutch IBD Biobank prospec-
tively collects 225 standardised data items on various 
topics, including patient demographics, family history, 
diagnosis, disease activity, disease localisation, results of 
physical examinations, radiographic imaging results, 
laboratory and endoscopy results, previous and current 
treatment, as well as a wide array of disease and treat-
ment complications. Validated questionnaires and scores, 
such as the Harvey-Bradshaw Index (HBI), the Simple 
Clinical Colitis Activity Index (SCCAI) and the Montreal 
classification are incorporated in the information model. 
This model contains both the IBD-related items as well 
as instructions on how to score these items. It has been 
shown that clinicians score subphenotypes of IBD simi-
larly, with a good to excellent interobserver agreement.9 
The information model is provided in English in online 
supplementary table 1 and can be downloaded in Dutch 
on the PSI website: www. parelsnoer. org. The Dutch IBD 
Biobank information model is regularly updated. The 
latest version is based on the coding system called Detailed 
Clinical Models (h ttp: //www. detailedclinicalmo dels . nl / 
dcm- en) and is called PRISMA (Parelsnoer Repository for 
Information Specification, Modelling, and Architecture).
Local databases and infrastructure
Each UMC has implemented the information model 
and collects and stores their patient information 
locally. As stated by the NFU, research data should be 
collected and registered directly at the source, that is, 
during the patient visit. Therefore, the data collection 
process should be incorporated into the clinical care 
structure.10 This approach has been gradually imple-
mented in each UMC depending on the capacities of 
their electronic health record (EHR) system. At the 
moment, each UMC has a procedure to extract, trans-
form and upload pseudonymised information of partic-
ipants to the PSI central database (figure 1). The UMCs 
are in different stages of having implemented the ‘at 
the source’ approach. In some UMCs it is already fully 
implemented, whereas in other UMCs this process has 
not yet begun. The first visit is prepared by a trained 
research nurse and since most of the 225 data items 
do not change during every visit, for example, family 
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history, medical doctors usually only need to register a 
subset of items during visits.
Central database and Central data Infrastructure
Pseudonymised information about study participants is 
stored in the Central Database, managed by the Advanced 
Data Management (ADM) section of the Department of 
Medical Statistics and BioInformatics of the LUMC.
The software ProMISe, a web-based relational database 
management system for the design, maintenance and use 
of clinical data management, is used to store the Central 
Database. (https://www. msbi. nl/ promise/). Researchers 
can access data in the Central Database following approval 
of their research proposal in secure web-based environ-
ment. Together, the Central Database and the web appli-
cation form the Central Data Infrastructure (figure 1).7
data upload and pseudonymisation
In each UMC, data are automatically uploaded from the 
Local Database to the Central Database at least once a 
month. During the upload process, pseudoanymisation is 
performed by a trusted third party (TTP). Only the TTP 
has access to key containing both the local identifiers and 
the Dutch IBD Biobank identifier. Prior to the upload, 
data validation is performed locally on a set of essential 
data items. If necessary, corrections are made locally and 
subsequently included in the next upload. A full audit 
trail is in place for the entire process.
Privacy and information security audits
ADM, the Central Database and the Central Data Infra-
structure software are audited according to Dutch 
NEN751011 international ISO 27.00112 information secu-
rity guidelines. ADM is audited twice per year while its 
software is periodically audited by Lloyds Register Quality 
Assurance, a certified independent auditor.
biomaterial collection
In addition to the data items, biomaterials are collected 
from all patients with IBD: including DNA, serum, faeces, 
mucosal biopsies and resection specimens when surgical 
procedures were required. Laboratory experts of all eight 
university hospitals convened to create uniform biomate-
rial collection and processing protocols. The biomaterials 
are stored in one of the eight local biobanks (figure 1). 
The biomaterial identifiers are uploaded to the Central 
Database and linked to the clinical data. Neither the local 
biomaterial identifiers nor the stickers on the bioma-
terial vials contain identifiable patient information. 
During the upload process, a unique additional bioma-
terial identifier is added to the local biomaterial identi-
fier in case multiple UMCs have a biomaterial with the 
same identifier. When a research project is approved, all 
eight local biobanks will send the required biomaterials 
to the researcher while the biomaterial identifiers linked 
to the clinical data can be downloaded using the secure 
web portal of the Central Infrastructure. If a biomaterial 
sample does not meet the required standards, the sample 
will be disposed. A brief summary of the biomaterial 
protocol is provided in table 1.7 The entire biomaterial 
protocols can be downloaded from www. parelsnoer. org, 
but are only available in Dutch.
Coordination
The Dutch IBD Biobank has two national coordinators 
and an assistant coordinator, who manage updates of the 
information model and the delivery of data and biomate-
rial to researchers (figure 1).
8 Uniform Clinical databases, using the same data model (one at each UMC)
8 Standardised Biomaterial Storages (one at each UMC)
IBD Scientific Committee
National IBD
Coordinator
 IBD Researchers
Central Infrastructure
  Clinical data storage
  Biomaterial IDs storage
IBD Data ro iding
Coordinator
Figure 1 Overview of the data and biomaterial infrastructure of the Dutch IBD Biobank, built by the Parelsnoer Institute in 
collaboration with all eight university medical centres (UMC) in the Netherlands. IBD, inflammatory bowel disease; ID, identifier.
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Informed consent
All patients with IBD who are treated in the Dutch UMCs 
are asked to participate in the Dutch IBD Biobank by 
their gastroenterologist during a visit to the outpa-
tient department of their UMC. If they are willing to 
participate, they are asked to sign an informed consent 
form (English translation in online supplementary 
document 1). Patients who choose to participate may 
revoke their consent at any point, after which their data 
and biomaterials will be removed from the Dutch IBD 
Biobank. Data and biomaterials that have already been 
sent to a researcher cannot be revoked, which is clearly 
stated in the patient informed consent form.
Patient enrolment
Patient enrolment started in January 2007 and is ongoing 
(table 2).
Not all patients were asked to join at once, but they 
were asked in batches so gastroenterologist and research 
nurses could manage the initial data registration.
Every patient with IBD enrolled has a proven IBD diag-
nosis according to the Lennard-Jones criteria.13 Diagnosis 
is confirmed by endoscopy, radiology and/or histology.
definitions
To create an overview of the content of the biobank, 
the characteristics of the patients were assessed. The 
following clinical and demographic items reported in this 
study are registered at the time of inclusion in the Dutch 
IBD Biobank and are referred to as baseline: first diag-
nosis, disease localisation, smoking status, employment 
status, gender, ethnicity, presence of a stoma or pouch, 
disease activity (modified HBI and modified SCCAI 
score) and date of birth. Disease localisation is scored 
according to the Montreal classification, which describes 
the maximum disease extent during entire disease course, 
and is registered at baseline. Disease localisation has to be 
confirmed by radiology, endoscopy or histology assess-
ment. The items dysplasia, bowel cancer, family history of 
IBD, current diagnosis and medication use described in 
this study were registered during the last follow-up visit before 
the data download in July 2014. Items describing disease 
behaviour, surgery, appendectomy, extraintestinal mani-
festations (EIM) and complications were registered over 
the entire disease course up to baseline. The definitions base-
line, last follow-up visit before the data download and over the 
entire disease course up to baseline are graphically explained 
in online supplementary figure 1.
statistical analyses
All descriptive statistics and statistical analyses are 
performed using Stata software V.13.1 (http://www. stata. 
com/). Continuous variables are expressed as medians 
and IQRs 25 and 75. Qualitative variables are presented 
as counts and frequencies. We compared outcomes 
between patients with CD and UC. Qualitative variables 
were analysed using the Pearson’s Χ2 test. Quantitative 
variables were analysed using the Mann-Whitney U test. T
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We performed a multivariate analysis of the effect of 
smoking on different outcomes in all patients with IBD. 
We corrected for covariates with p<0.20 in the univar-
iate analyses (age, gender, diagnosis, disease duration 
and prior anti-tumour necrosis factor use). The statis-
tical models were built using backward selection: covari-
ates that were not statistically significantly influencing 
the outcome variable (p>0.05) were removed from the 
model. We then applied the same strategy to patients with 
CD and UC separately to correct for disease activity. A 
p Value <0.05 was considered statistically significant.
Follow-up
Clinical and demographical follow-up data are collected 
at every visit to an outpatient department. Usually, 
patients with IBD in the Netherlands are seen by a gastro-
enterologist twice a year. This is standard clinical care 
following treatment protocols used in every UMC. The 
disease course is heterogeneous, as a consequence, data 
available on follow-up can be extensive for one patient 
but more limited for another. If requested by the gastro-
enterologist, a blood sample is taken. Furthermore, if 
required, intestinal mucosal biopsies are collected during 
endoscopy and resection specimens are obtained during 
surgery.
FIndIngs to dAte
Consent rate and differences between participants and non-
participants
We first assessed possible differences between patients 
with IBD willing to participate in the Dutch IBD Biobank 
and patients with IBD who did not want to participate. 
To do so, a subset at one UMC (UMCG) was downloaded 
and analysed. This subset was used because privacy guide-
lines do not allow data of participants not wishing to 
take part to be uploaded to the PSI central database. On 
17 July 2014, after the first data download, 786 patients 
were asked to participate in the UMCG. Of these, 742 
patients with IBD gave their informed consent while 44 
patients with IBD declined to participate. The consent 
rate was 93.4%. Table 3 provides an overview of the char-
acteristics of those who consented to participate and those 
who did not. Of the 742 patients who consented, 625 
were used in the analysis of the 2014 data because they 
met the selection criteria (clear IBD diagnosis, known 
date of birth and gender, informed consent and isolated 
DNA available including a biomaterial identifier). The 
characteristics of the consenting and non-consenting 
patients were similar. Only disease location according to 
the Montreal classification was statistically significantly 
different between these two groups (p=0.037, Χ2 test).
the characteristics of the dutch patients with Ibd in uMCs
A download of data on 17 July 2014 was analysed to 
explore the demographic and clinical characteristics 
of the cohort recruited to that date. It included 3388 
patients with IBD: 2118 CD (62.5%), 1190 UC (35.1%), T
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Table 3 Baseline characteristics of the responders and non-responders recruited through the University Medical Center 
Groningen on 17 July 2014
n (%)
IBD (CD, UC, IBD-U) CD UC
Responders
n 742 (100%) 411 (55%) 294 (40%)
Sex 742 (100%) 411 (100%) 294 (100%)
  Male 305 (41%) 141 (34%) 142 (48%)
  Female 437 (59%) 270 (66%) 152 (52%)
Age of onset median years (IQR 25–75) 26.8 (20–38) 24.5 (19–35) 30.6 (23–41)
Disease duration at inclusion median years (IQR 25–75) 8.2 (4–15) 9.3 (4–15) 7.6 (4–14)
Disease location (according to Montreal)
Crohn’s disease 411 (100%)
A1: diagnosis ≤16 years 58 (14%)
A2: diagnosis 17–40 years 278 (68%)
A3: diagnosis >40 years 75 (18%)
L1: ileal disease† 148 (37%)
L2: colonic disease† 85 (22%)
L3: ileocolonic disease† 163 (41%)
L4: upper GI disease‡ 41 (10%)
P: perianal 130 (32%)
B1: non-stricturing, non-penetrating 211 (51%)
B2: stricturing 134 (33%)
B3: penetrating 66 (16%)
Ulcerative colitis 288 (100%)
E1: proctitis 40 (14%)
E2: left-sided colitis 92 (32%)
E3: extensive colitis 156 (54%)
Non-responders
n 44 (100%) 25 (57%) 16 (36%)
Sex 44 (100%) 25 (100%) 16 (100%)
  Male 16 (36%) 9 (36%) 5 (31%)
  Female 28 (64%) 16 (64%) 11 (69%)
Age of onset median years (IQR 25%–75%) 30.3 (19–42) 19.6 (17–39) 33.3 (25–42)
Disease duration at inclusion median years (IQR 25%–75%) 8.1 (4–12) 7.2 (3–12) 8.8 (5–13)
Disease location (according to Montreal guidelines)
Crohn’s disease 25 (100%)
A1: diagnosis ≤16 years 7 (28%)
A2: diagnosis 17–40 years 12 (48%)
A3: diagnosis >40 years 6 (24%)
L1: ileal disease* 4 (16%)
L2: colonic disease* 10 (40%)
L3: ileocolonic disease* 11 (44%)
L4: upper gastrointestinal disease 0 (0%)
P: perianal 9 (36%)
B1: non-stricturing, non-penetrating 11 (44%)
B2: stricturing 10 (40%)
Continued
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74 IBD-unclassified (2.2%) and 6 IBD-indetermi-
nate (0.2%). The median age of patients with IBD at 
inclusion was 42 years old (IQR 32–54 years) (tables 4-6). 
In all, 93% of patients are of Central European Cauca-
sian descent and the other 7% are of African, Hindustani, 
Moroccan, Turkish, Asian, Jewish, other western, other 
non-western or mixed descent. Smoking status at the time 
of first IBD diagnosis was registered for 3021 patients 
with IBD (89%), and more patients with CD smoked 
compared with patients with UC (44% CD, 18% UC, 
p<0.001). Patients with UC were more likely to have quit 
smoking in the 6 months prior to the first IBD diagnosis 
(1.0% CD, 4% UC, p<0.001). Ileocolonic disease in 
patients with CD (46%) (figure 2) and extensive colitis 
(E3) in patients with UC (56%) (figure 3) are more 
common in our cohort than in other studies (figures 4 
and 5).14–18  The high number of patients with extensive 
disease in our cohort can be explained by a selection bias 
(tertiary referral centres). The disease locations in CD 
were similar in men and women (figure 6).
Moreover, the most extensive disease during the entire 
disease duration (Montreal L (disease location) in patients 
with CD and Montreal E (disease extent) in patients with 
UC) is well documented in the Dutch IBD Biobank, while 
other studies often only report disease extent at the time 
of diagnosis (median disease duration in the Dutch IBD 
Biobank is 12 years). EIMs are more common in patients 
with CD than in patients with UC, which we corroborated 
n (%)
IBD (CD, UC, IBD-U) CD UC
B3: penetrating 4 (16%)
Ulcerative colitis 15 (100%)
E1: proctitis 5 (33%)
E2: left-sided colitis 5 (33%)
E3: extensive colitis 5 (33%)
*p=0.037.
†These percentages were calculated for 396 patients with CD (responders).
‡These percentages were calculated for 402 patients with CD (responders). 
CD, Crohn’s disease; GI, gastrointestinal; IBD, inflammatory bowel disease; IBD-U, inflammatory bowel disease-unclassified; UC, ulcerative 
colitis.
Table 3 Continued 
Table 4 Demographic characteristics of patients with inflammatory bowel disease in the Dutch IBD Biobank cohort on 
17 July 2014
n (%)
IBD (CD, UC, IBD-I, IBD-U) CD UC
n 3388 (100%) 2118 (62%) 1190 (35%)
Sex 3388 (100%) 2118 (100%) 1189 (100%)
  Male 1377 (41%) 773 (36%)* 566 (48%)*
  Female 2010 (59%) 1345 (64%)* 623 (52%)*
Age at inclusion median years (IQR 25–75) 42.5 (32–54) 41.1 (31–53)* 45.5 (34–56)*
Ethnicity 3323 (100%) 2073 (100%) 1170 (100%)
Caucasian 3090 (93%) 1930 (93%) 1084 (93%)
Other 233 (7%) 143 (7%) 86 (7%)
Non-IBD surgery
  Appendectomy† 394 (12%) 313 (15%)* 76 (6%)*
Smoking status at diagnosis 3021 (100%) 1910 (100%) 1037 (100%)
Current smoker 1052 (35%) 846 (44%)* 190 (18%)*
Former smoker (<6 months) 60 (2%) 19 (1.0%)* 40 (4%)*
Former smoker (>6 months) 601 (20%) 254 (13%)* 328 (32%)*
Never smoked 1308 (43%) 791 (42%)* 479 (46%)*
*p<0.001.
†Missing values were scored as absent.
CD, Crohn’s disease; GI, gastrointestinal; IBD, inflammatory bowel disease; IBD-I, inflammatory bowel disease-indeterminate; IBD-U, 
inflammatory bowel disease-unclassified; UC, ulcerative colitis.
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Table 5 Clinical characteristics, extraintestinal manifestations and complications in patients with inflammatory bowel disease 
in the Parelsnoer Institute cohort
n (%)
IBD CD UC
n 3388 (100%) 2118 (62%) 1190 (35%)
Disease characteristics
  Age of onset median years (IQR 25–75) 26.4 (20–37) 24.6 (19–33)** 30.1 (22–41)**
  Disease duration at inclusion median years (IQR 25–75) 11.5 (5–20) 12.2 (6–22)** 10.7 (5–19)**
  Family history of IBD 932 (28%) 613 (29%)* 301 (25%)*
Disease location (Montreal classification)
  L1: ileal diseasea 379 (23%)
  L2: colonic diseasea 518 (31%)
  L3: ileocolonic diseasea 780 (46%)
  L4: upper GI disease† 177 (8%)
  P: perianal† 563 (27%)
  E1: proctitisb 82 (8%)
  E2: left-sided colitisb 357 (36%)
  E3: extensive colitisb 558 (56%)
Pouch† 155 (5%) 38 (2%) 112 (9%)
Disease activity at inclusion
  mHBI scorec 1828 (100%)
  Remission 0–4 1218 (67%)
  Mild disease 5–7 314 (17%)
  Moderate disease 8–16 274 (15%)
  Severe disease >16 22 (1.2%)
  mSCCAI scored 1016 (100%)
  Remission <2.5 752 (74%)
  Active disease ≥2.5 264 (26%)
Liver disease due to IBD 3388 (100%) 2118 (100%) 1190 (100%)
  Primary sclerosing cholangitis (PSC)† 71 (2%) 25 (1.2%)** 43 (4%)**
  Liver disease other than PSC† 65 (1.9%) 42 (2.0%) 22 (1.8%)
Extraintestinal manifestations 3388 (100%) 2118 (100%) 1190 (100%)
  Skin manifestations†e 336 (10%) 250 (12%)** 80 (7%)**
  Musculoskeletal manifestations†f 731 (22%) 513 (24%)** 204 (17%)**
  Ocular manifestations†g 147 (4%) 104 (5%)* 38 (3%)*
Complications 3388 (100%) 2118 (100%) 1190 (100%)
  Osteopenia (T score ≤1)† 676 (20%) 496 (23%)** 169 (14%)**
  Thromboembolic events† 119 (4%) 76 (4%) 42 (4%)
aPercentages calculated for 1677 patients with CD.
bPercentages calculated for 997 patients with UC.
cmHBI: modified Harvey-Bradshaw Index score; patients with CD were asked to rate their well-being on a scale from 1 to 10 (1: feeling terrible to 10: feeling 
very good) and to rate abdominal pain on a scale from 0 to 10 (0: no abdominal pain to 10: worst pain imaginable). Patients were also asked to provide data 
on diarrhoea frequency. In addition, patients were asked about the presence of oral aphthous lesions, active abscesses and fistulae as well as extraintestinal 
manifestations (arthralgia, uveitis, erythema nodosum, pyoderma gangrenosum). The physician assessed the presence of anal fissures and evaluated 
possible abdominal resistance through physical examination. mHBI data were available on 1828 patients (100%).
dmSCCAI: modified Simple Clinical Colitis Activity Index score; patients with UC were asked to rate their well-being on a scale from 1 to 10 (1: feeling terrible 
to 10: feeling very good). In addition, patients were asked to describe the defecation frequency during the day and during the night, the defecation urgency 
(yes or no), the presence of blood in their stool (yes or no) and extracolonic manifestations (arthritis, uveitis, erythema nodosum, pyoderma gangrenosum).
eThe following skin manifestations associated with IBD were scored: pyoderma gangrenosum, erythema nodosum, hidradenitis suppurativa, psoriasis or 
palmoplantar psoriasiform pustulosis and metastatic CD. Which type was not specified, only the presence of a skin manifestation.
fMusculoskeletal manifestations were divided into two groups: (1) arthritis (red and swollen joints), for example, dactylitis, reactive arthritis, gout; (2) 
arthropathy (not red or swollen joints, but symptoms with an inflammatory pattern; pain at night or at rest), for example, sacroiliitis, ankylosing spondylitis, 
enthesitis and inflammatory back pain.
gOcular manifestations comprised uveitis and episcleritis diagnosed by a doctor. Which eye condition was not specified, only the presence of an ocular 
manifestation.
*p<0.05; **p<0.001.
†Missing values were scored as non-present.
CD, Crohn’s disease; GI, gastrointestinal; IBD, inflammatory bowel disease (CD+UC+IBD-I (indeterminate)+IBD-U (unclassified)); UC, ulcerative colitis.
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Table 6 Malignancies, surgery and medication use of patients with inflammatory bowel disease in the Parelsnoer Institute 
cohort
IBD CD UC
n (%) 3388 (100%) 2118 (62%) 1190 (35%)
Malignancy 3388 2118 1190
  Dysplasia, na 131 62 63
  Bowel cancer, nb 15 9 5
Surgery 3388 (100%) 2118 (100%) 1190 (100%)
  (Segmental) small bowel resection† 252 (7%) 242 (11%) 10 (0.8%)
  Ileocaecal resection† 759 (22%) 758 (36%) –
  (Segmental) colon resection† 591 (17%) 368 (17%) 212 (18%)
  Resection other† 168 (5%) 139 (7%) 28 (2%)
  Strictureplasty† 99 (3%) 89 (4%) –
  Ileostomy/colostomy† 414 (12%) 283 (13%) 123 (10%)
  Surgery for abscesses or fistulas† 494 (15%) 467 (22%) 27 (2%)
Outcome postsurgery 3388 (100%) 2118 (100%) 1190 (100%)
  Stoma† 402 (12%) 270 (13%) 121 (10%)
Disease recurrence after IBD surgery
  Neoterminal ileumc 393 (52%) 393 (52%) –
  Ileocolonic anastomosisd 56 (7%) 56 (7%) –
  Pouchitise 93 (60%) 22 (58%) 67 (60%)
Surgical complication 1187 (100%) 959 (100%) 216 (100%)
  Stricture anastomosisf 122 (10%) 107 (11%) 15 (7%)
Medication use during disease course 3306 (100%) 2068 (100%) 1158 (100%)
  Immunomodulatorsg 2216 (67%) 1513 (73%)** 664 (57%)**
  Biologicalsh 1274 (39%) 1027 (50%)** 231 (20%)**
  Azathioprinei 1374 (42%) 951 (46%)** 398 (34%)**
  Mercaptopurinej 276 (8%) 199 (10%)** 73 (6%)**
  Both azathioprine and mercaptopurinek 270 (8%) 172 (8%) 90 (8%)
  Thioguaninel 114 (3%) 62 (3%) 50 (4%)
  Methotrexatem 423 (13%) 363 (18%)** 52 (4%)**
aDysplasia had to be confirmed in an intestinal biopsy by a pathologist. All intestinal biopsies were included including those 
from polyps.
bBowel cancer included colorectal cancer, small bowel cancer and anal cancer.
cPercentage of disease recurrence in neoterminal ileum calculated from total patients with an ileocaecal resection (n=759 IBD, 
n=758 CD).
dPercentage of disease recurrence in ileocolonic anastomosis (no disease recurrence in neoterminal ileum) calculated from 
total patients with an ileocaecal resection (n=759 IBD, n=758 CD).
ePercentage of pouchitis calculated from total pouches (n=155 IBD, n=38 CD, n=112 UC).
fTotal patients who underwent surgery (small bowel resection, Ileocaecal resection, colon resection or resection other) 
(n=1187 IBD, n=959 CD, n=216 UC).
gImmunomodulators: patients used one of the following immunosuppressives: azathioprine, Imuran, mercaptopurine, 
Purinethol, methotrexate, Metoject, thioguanine, Lanvis.
hBiologicals: patients used one of the following anti-tumour necrosis factors: infliximab, adalimumab or certolizumab.
iAzathioprine: patients used azathioprine or Imuran.
jMercaptopurine: patients used mercaptopurine or Purinethol.
kBoth azathioprine and mercaptopurine: patients used azathioprine and/or Imuran and mercaptopurine and/or Purinethol. It 
was unclear which one of the drugs was used first.
lThioguanine: patients used thioguanine or Lanvis.
mMethotrexate: patients used methotrexate or Metoject.
**p<0.001.
†Missing values were scored as non-present.
CD, Crohn’s disease; IBD, inflammatory bowel disease (CD+UC+IBD-I (indeterminate)+IBD-U (unclassified)); UC, ulcerative 
colitis.
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in the Dutch IBD Biobank data (figure 7).19–21 We found 
that patients with UC who smoked more often suffered 
from ocular manifestations and arthropathy than those 
who did not smoke, matching previous findings.22 23 An 
increased risk of EIM in patients with CD who smoked has 
previously been reported,24 but we could not confirm this 
result in our cohort.
genetic predictor of a fibrostenotic or inflammatory disease 
course in Cd
The availability of genomic data and detailed clinical data 
in the Dutch IBD Biobank enabled a GWAS that aimed to 
find genetic predictors for recurrent fibrostenotic disease 
in patients with CD, by comparing the extremes of the 
clinical spectrum: (1) patients with CD with a mild disease 
course defined by inflammation without any signs of stric-
turing or penetrating disease during the last 5 years, versus 
(2) patients with CD who underwent ileocaecal resection 
due to confirmed intestinal strictures at least twice. We iden-
tified a genetic variant in the WWOX gene that regulates 
fibrosis through the SMAD pathway. The WWOX gene could 
therefore be an important signalling modulator involved 
in fibrostenotic CD (Resubmitted to the Journal of Crohn’s and 
Colitis).
Previously published finding: Rare variants in MUC2 are asso-
ciated with UC in the Dutch population. A subsequent study 
aimed to identify rare genetic variants with a large effect 
on UC susceptibility. Pooled resequencing of 122 genes 
in UC susceptibility loci in 1021 Dutch UC cases and 1166 
Dutch controls revealed that rare variants in the MUC2 
gene were associated with increased UC susceptibility 
(gene-based analysis with SKAT-O, nine variants in the 
MUC2 gene: p value of 9.2×10−5; threshold p=0.0011 after 
Bonferroni correction). Interestingly, this association 
Figure 2 Disease localisation in patients with Crohn’s 
disease in the Dutch IBD Biobank according to the Montreal 
classification. GI, gastrointestinal.
Figure 3 Disease localisation in patients with ulcerative 
colitis in the Dutch IBD Biobank according to the Montreal 
classification.
Figure 4 Date of Crohn’s disease diagnosis and of disease 
location (L) according to the Montreal classification. L1, ileal; 
L2, colonic; L3, ileocolonic.
Figure 5 Date of ulcerative colitis diagnosis and of 
disease extent (E) according to the Montreal classification. 
E1, proctitis; E2, left-sided colitis; E3, pancolitis.
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appeared to be population specific for the Netherlands.25 
Using the same approach and samples, a protein trun-
cating variant in RNF186 that protects against UC was also 
identified.26
Associations between genetic variants and subphenotypes  
of Ibd
The Dutch IBD Biobank participated in a large study where 
the clinical characteristics of patients with IBD were asso-
ciated to genetic variants. The discovery of genetic vari-
ants associated with specific disease location and disease 
behaviour was published in the Lancet.27
gWAs and sequencing studies investigating the Ibd diagnosis 
using dnA collections that were integrated in the dutch Ibd 
biobank
For 1904 participants of the Dutch IBD Biobank genotype 
data are available consisting of ~200 000 single nucleotide 
polymorphisms (SNP) obtained using the Immunochip, 
an Illumina genotyping array focused on immune-medi-
ated diseases. These genotype data were used in landmark 
genetic studies published in Nature and Nature Genetics 
investigating IBD pathogenesis.3 28–30 These studies led 
to the discovery of 200 genetic loci associated with IBD, 
explaining 21.3% of the onset of IBD.
dIsCussIon: strengths And WeAknesses oF the dutCh 
Ibd bIobAnk
strengths
A major strength of the Dutch IBD Biobank is its prospec-
tive design and extensive uniform information model 
comprising 225 data items, and the participation of all 
eight UMCs in the Netherlands. In addition, the biomate-
rials such as serum, DNA and a stool sample are collected 
at baseline, and, if available, biopsies from endoscopy and 
resection tissue are collected during follow-up, allowing 
the integration of subphenotypes enabling biomarker 
discovery research.
Since IBD is a chronic disease that requires lifelong 
treatment, patients treated in tertiary centres are rarely 
referred back to a general or local hospital and therefore 
loss to follow-up is uncommon.
barriers to establishment and limitations
Setting up the Dutch IBD Biobank required a tremendous 
effort and there were many barriers to establishment. 
While some of these barriers were overcome, some limita-
tions of the Dutch IBD Biobank remain. After a large initial 
grant provided by the Dutch government to the Nether-
lands Federation of University Medical Centres facilitating 
the establishment of the Dutch IBD Biobank and seven 
similar biobanks ended in 2011, the Dutch UMCs had to 
fund the continuation of the Dutch IBD Biobank them-
selves, meaning a reduction of staff that assisted in patient 
inclusion in some centres. As a consequence, the enrol-
ment of patients has slowed down in these centres.
A major challenge was the establishment of the infor-
mation technology (IT) infrastructure. In all UMCs, the 
local EHRs needed to be adapted so that the necessary 
information could be extracted. The gradual process of 
implementing data collection ‘at the source’ during the 
patient visit, and the renewal of EHRs in several hospi-
tals means that adaptations to the local IT infrastructure 
continue to be necessary. Similar projects should be 
aware that the investments in the IT infrastructure will 
be ongoing after the establishment, and make sure they 
anticipate that continuous funding is required.
data completeness, data similarity, data validation, quality 
control and feedback
A large majority of the data items were completely scored 
as can be seen in tables 3-6. However, the different 
Figure 6 Disease location (L) according to the Montreal 
classification stratified by sex in patients with Crohn's 
disease (CD). L1, ileal; L2, colonic; L3, ileocolonic.
Figure 7 Extraintestinal manifestations and complications of 
patients with inflammatory bowel disease (IBD) in the Dutch 
IBD Biobank.
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collection approaches by different UMCs sometimes lead 
to small differences in the clinical data, as some items 
were scored differently. Prior to completing this study, 
the authors reviewed all data and reported all inconsis-
tencies to the national coordinators and to all UMCs. 
Several gastroenterologists, research nurses and IT 
departments improved the local data and a new upload 
to the Central Database was performed. Initially, very 
strict data validation steps were included in the Central 
Database software. However, these validation steps were 
too strict, and, because clinical patient records are often 
imperfect, very few patient records could be uploaded to 
the Central Database. After being aware of this problem, 
all data validation steps were removed from the Central 
Database software. Unfortunately, the lack of data valida-
tion steps led to errors in the data. Now, a small set of data 
validation protocols is in place. We recommend similar 
initiatives to start with simple data validation protocols 
and gradually expand these as the data quality and collec-
tion protocols improve.
selection bias
Because all tertiary referral centres in the Netherlands 
participate in the Dutch IBD Biobank, the cohort will 
contain a large fraction of patients with IBD with a more 
severe disease course. This IBD cohort is not therefore 
suitable for studies that require a population-based 
cohort, for example, studies on the incidence and preva-
lence of IBD manifestations.
CoLLAborAtIon
IBD researchers of the Dutch UMCs can access the Dutch 
IBD Biobank data and biomaterials after their research 
proposal has been approved by the Scientific Committee 
of the Dutch IBD Biobank. Other researchers can use the 
data and biomaterials of the Dutch IBD Biobank, but have 
to establish a cooperation with one or more Dutch UMCs.
research proposal and application process
Research proposals can be submitted to the Scientific 
Committee and the Institutional Review Board. Proposals 
are judged against the following criteria:
a. It is reasonably plausible that the proposed research 
could lead to new insights.
b. The aims in the research proposal can be met using 
the proposed research methodology.
c. The proposed research is in concordance with the 
patient informed consent.
d. The proposed research will be conducted by people 
in institutes and facilities that are skilled and able to 
conduct the research.
e. The research proposal does not request more data 
and biomaterials than necessary.
f. The research proposal meets reasonable standards.
g. The proposed research does not unacceptably 
conflict or overlap with other research proposals.
After the Scientific Committee has approved a 
research proposal, the data manager will provide the 
pseudonymised research data in the web-based environ-
ment, and will facilitate the biomaterial delivery to the 
researcher. Applicants do not have to pay a fee.
The Dutch IBD Biobank can be contacted via email: 
IBDParel@ umcg. nl. More information can also be found 
on the PSI website: www. parelsnoer. org. The Dutch 
IBD Biobank aims to cooperate with international IBD 
research groups. The information model and the list 
of biomaterials are publicly available and can be down-
loaded from the PSI website. The Dutch IBD Biobank 
encourages other biobanks to use the same information 
model and biomaterial collection standards to enable 
larger international studies on IBD and we encourage 
similar initiatives to contact us in an early stage.
Future deveLoPMents
genotyping the entire dutch Ibd biobank
All DNA samples are in the process of being genotyped 
with a newly developed genome-wide genotyping array 
from Illumina, containing 750 000 SNPs. These data 
will be leveraged by imputation against whole genome 
sequence data of 700 Dutch individuals studied in the 
Genome of the Netherlands project.31 The availability of 
the genotype data will enable more genetic studies.
Web-based data access for researchers
The Dutch IBD Biobank is working on a multiomics data 
sharing portal called the Molgenis Research IBD Portal, 
based on Molgenis software.32 This portal will make 
summary level statistics publicly available.
Mobile app for patients
The web-based follow-up of Patient-Reported Outcome 
Measurements including clinical disease activity scores 
is another project that the Dutch IBD Biobank is imple-
menting. Patients will regularly fill in online question-
naires on disease activity, treatment response, quality of 
life and quality of care. Several UMCs are using the app 
My IBD Coach: http://www. sananet. nl/ mijn- ibd- coach. 
html. The use of this app for IBD eHealth was extensively 
tested in a trial led by the MUMC, the Netherlands, where 
it was proven effective in reducing the number of hospital 
admissions.33
ConCLusIons
The Dutch UMCs have together created a biobank 
containing data and biomaterials of more than 3000 
patients with IBD. The creation of the Dutch IBD 
Biobank took a very large multicentre multiyear effort, 
and new projects continue to improve the infrastructure 
and data collection. The main objective of the biobank 
is to facilitate the biomarker discovery. By now, studies 
using the Dutch IBD Biobank have led to the discovery 
a genetic predictor of a more severe disease course in 
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patients with CD, showing that combining -omics data with 
prospectively collected clinical records can lead to useful 
results. Whether the standardising of patient data collec-
tion and during the patient visits and questionnaires 
online improves the clinical care of patients with IBD 
in the Netherlands is not yet known, but studies investi-
gating the use of online disease activity scores and early 
detection of IBD exacerbations in the Netherlands are 
showing a reduction in hospitalisations.33 We encourage 
researchers who want to establish similar biobanks to 
contact us, and to take our important recommendations, 
including the continuous IT funding, and the step-by-step 
implementation of data quality measures described in the 
discussion, into account.
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